|
1. Biologie
|
|
|
|
New insight into origin of stomach cancer [WUSTL]
|
|
|
|
|
|
In
this study, Burclaff and Mills inserted a human gene into
acid-secreting cells in the stomachs of mice. Then, by exposing the
animals to a toxin that affects human cells but not mouse cells, they
were able to kill the acid-secreting cells without damaging any other
cells in the animals. But, surprisingly, the mice did not go on to
develop the precancerous condition.
|
|
|
|
|
|
|
|
|
2.11 Etiologie - Alimentation
|
|
|
|
|
3.1 Tabac
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
5.12 Immunothérapies
|
|
|
Opdivo Shows Appetite for Gastric Cancer [OBR Blog]
|
|
|
|
|
|
While
gastric cancer is a relatively rare tumor type in the United States
(ranks 16th in terms of incidence), it is the most commonly diagnosed
tumor type in Japan. In part due to this, Ono Pharmaceuticals took the
lead in evaluating immunotherapy in gastric cancer in Asia Pacific.
|
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
22 Case Studies Where Phase 2 and 3 Results Diverge: New FDA Report [RAPS]
|
|
|
|
|
|
FDA
says the report “is not intended to assess why each of these unexpected
results occurred or why further product development was not pursued,”
but to “illustrate the ways in which controlled trials of appropriate
size and duration contribute to the scientific understanding of medical
products.”
|
|
|
|
|
|
|
22 Case Studies Where Phase 2 and Phase 3 Trials had Divergent Results [FDA]
|
|
|
|
|
|
To
better understand the nature of the evidence obtained from many phase 2
trials and the contributions of phase 3 trials, we identified, based on
publicly available information, 22 case studies of drugs, vaccines and
medical devices since 1999 in which promising phase 2 clinical trial
results were not confirmed in phase 3 clinical testing.
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
6. Lutte contre les cancers
|
|
|
Bernard Merkel: Should patients really be at the centre of healthcare? [BMJ Blogs]
|
|
|
|
|
|
So
when I hear this kind of discussion between academics and articulate
patient advocates in a room full of well-off, well-educated people with
considerable knowledge of health and healthcare, I can’t help but feel
that this is all a very long way from the more prosaic reality of the
less advantaged and more typical patients who turn up every day to GP’s
surgeries and A&E departments looking for expert help.
|
|
|
|
|
|
|
Cancer patients with depression have resources [Reuters]
|
|
|
|
|
|
The
patient resource explains that physical changes, limitations from
symptoms and treatment and uncertainty about the future all put cancer
patients at risk for depression. But nontherapeutic tools, such as
physical activity, a healthy diet, and a strong social network can help
the body, improve mood and reduce stress, the authors write.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.11 Patients
|
|
|
|
6.2 Implants mammaires
|
|
|